Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|March 9, 2026

The BioPharm Brief: FDA Priority Review and Trispecific Antibodies Advance Precision Oncology

Today’s podcast covers Phase II trispecific antibody data and evolving ADC strategies, which highlight durable, patient-centric approaches reshaping next-generation oncology therapy pipelines.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research and clinical innovation. Today’s podcast highlights advances in targeted oncology therapies, from antibody‑drug conjugates, or ADCs, to next‑generation multispecific antibodies, and how these innovations are moving through regulatory and clinical pathways.

First, FDA has granted priority review for AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan (brand name Enhertu) in early‑stage HER2‑positive breast cancer. The designation accelerates the regulatory timeline for the ADC, which links a cytotoxic payload to a HER2‑targeted antibody. Priority review reflects the potential for trastuzumab deruxtecan to address unmet medical needs in early breast cancer, building on prior approvals in metastatic settings and reinforcing the growing role of targeted ADCs in expanding precision oncology options.

In parallel, Pfizer released Phase II clinical data supporting the development of a once‑monthly trispecific antibody designed for oncology indications. The therapy is engineered to engage three separate immune targets simultaneously, aiming to enhance anti‑tumor immune responses while reducing treatment frequency. Early data suggest favorable pharmacokinetics and a manageable safety profile, positioning the approach as a potential next‑generation immunotherapy capable of improving patient convenience and long-term treatment adherence.

Taken together, these stories illustrate how precision targeting and multispecific immunotherapies are reshaping oncology pipelines. From accelerated regulatory pathways for ADCs to innovative multi‑target antibodies, developers are pursuing strategies that optimize efficacy, durability, and patient-centric treatment design.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments:

  • FDA priority review fast-tracks trastuzumab deruxtecan for early-stage HER2-positive breast cancer.
  • Pfizer’s once-monthly trispecific antibody shows promising Phase II results for multi-target immunotherapy.
  • Next-generation oncology therapies increasingly focus on precision, durability, and patient convenience.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more